Monthly Archives: December 2009

FFA-ers, Submit Your “Sustainability” Videos By December 31st!

On the National FFA Organization website, FFA promotes its new “Sustainability Through Biotechnology” Video Contest.  Students can get all the necessary information explaining how they can help show off their chapter’s knowledge and creativity! To participate, students are asked to submit a video (approximately two to three minutes in length) that shows the world how modern agricultural techniques are helping our planet.  It’s a great way to work on ag communications skills and learn more Read More >

Farmer Gene  |  Leave a comment  |  Email This Post

Small Biotechs Spending Less

The median and mean operational cash spending for small public US biotechs (less than 250 employees) is down 37% and 42% respectively, since the 1st Quarter of 2008. Company cut backs have shown up in the lay-off numbers as well as in the number of drug development projects put on hold. These quarterly numbers give a sense of the direction. For a look at the annual data, here is how spending breaks down for the Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , ,

Biotech in the Blogosphere

New Mexico is ready to develop a biofuels plan according to KRQE.com and the Associated Press, They write, “New Mexico’s elected officials want to develop a strategic plan to make the state a leader in the biofuels industry. Gov. Bill Richardson said New Mexico is in a good position when it comes to biofuels, given its combination of economic policies, business infrastructure, natural resources and scientific expertise. State leaders and the Southwestern Biofuels Association are Read More >

Biofuels & Climate Change  |  Leave a comment  |  Email This Post
Tags: , ,

1 in 4 Biotechs Above 100% – Waterfall Chart YTD

Year to date,  27% of biotech stocks have doubled in price. 65% are in positive territory in 2009, a strong contrast to the YTD data last year:

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,

The Rise and Fall of Undervaluation

If “price to cash” is a usable metric for fair value of a risky biotech (i.e. valuation of a biotech vs what its cash balance is at the bank), then the cheap times are long gone. Back at the end of 2008 we had a record 24% of biotechs trading below cash. Investors were making the assumption that the previous reported cash balance was already being spent and additions to the balance were in jeopardy. Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , ,